Arrowhead Pharmaceuticals Inc Total Liabilities
Arrowhead Pharmaceuticals Inc total liabilities. Based on the latest financial reports, Arrowhead Pharmaceuticals Inc (ARWR) has total liabilities worth $881.88 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See ARWR days of operational coverage to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Arrowhead Pharmaceuticals Inc (1997–2025)
Total liabilities of Arrowhead Pharmaceuticals Inc from 1997 to 2025. This chart illustrates how Arrowhead Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. Check ARWR financial resilience to evaluate the company's liquid asset resilience ratio.
Arrowhead Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Arrowhead Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Blueprint Medicines Corp
NASDAQ:BPMC
|
USA | $853.47 Million |
|
Restaurant Brands International Limited Partnership
TO:QSP-UN
|
Canada | CA$19.59 Billion |
|
Bid Corporation Ltd
JSE:BID
|
South Africa | ZAC73.29 Billion |
|
Element Solutions Inc
NYSE:ESI
|
USA | $2.96 Billion |
|
Redeia Corporacion S.A.
MC:RED
|
Spain | €10.33 Billion |
|
Pentair PLC
NYSE:PNR
|
USA | $2.96 Billion |
|
Companhia Paranaense de Energia - COPEL
SA:CPLE3
|
Brazil | R$38.18 Billion |
|
American Airlines Group
NASDAQ:AAL
|
USA | $68.20 Billion |
Liability Composition Analysis (1997–2025)
This chart breaks down Arrowhead Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see balance sheet size of Arrowhead Pharmaceuticals Inc.
Liquidity & Leverage Metrics
Arrowhead Pharmaceuticals Inc Total Liabilities Ratios Explained
Arrowhead Pharmaceuticals Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.86 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.89 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.64 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Arrowhead Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Arrowhead Pharmaceuticals Inc (1997–2025)
The table below shows the annual total liabilities of Arrowhead Pharmaceuticals Inc from 1997 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-09-30 | $947.02 Million | -0.18% |
| 2024-09-30 | $948.74 Million | +98.32% |
| 2023-09-30 | $478.39 Million | +74.85% |
| 2022-09-30 | $273.60 Million | -9.20% |
| 2021-09-30 | $301.33 Million | +396.22% |
| 2020-09-30 | $60.72 Million | -42.61% |
| 2019-09-30 | $105.81 Million | +546.40% |
| 2018-09-30 | $16.37 Million | -29.31% |
| 2017-09-30 | $23.16 Million | -30.16% |
| 2016-09-30 | $33.15 Million | +46.39% |
| 2015-09-30 | $22.65 Million | +34.55% |
| 2014-09-30 | $16.83 Million | +45.16% |
| 2013-09-30 | $11.59 Million | +50.21% |
| 2012-09-30 | $7.72 Million | +132.19% |
| 2011-09-30 | $3.32 Million | -22.26% |
| 2010-09-30 | $4.28 Million | +50.35% |
| 2009-09-30 | $2.84 Million | -42.57% |
| 2008-09-30 | $4.95 Million | +45.83% |
| 2007-09-30 | $3.40 Million | +16.30% |
| 2006-09-30 | $2.92 Million | +185.16% |
| 2005-09-30 | $1.02 Million | +48.48% |
| 2004-09-30 | $689.70K | +617.11% |
| 2003-09-30 | $96.18K | -94.04% |
| 2002-09-30 | $1.61 Million | +19.50% |
| 2001-09-30 | $1.35 Million | +13.10% |
| 2000-09-30 | $1.19 Million | +10.75% |
| 1999-09-30 | $1.08 Million | -60.24% |
| 1998-09-30 | $2.71 Million | +1.07% |
| 1997-09-30 | $2.68 Million | -- |
About Arrowhead Pharmaceuticals Inc
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, a… Read more